These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 37109714

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Development of Two Novel One-Step and Green Microwell Spectrophotometric Methods for High-Throughput Determination of Ceritinib, a Potent Drug for Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.
    Abuhejail RM, Alzoman NZ, Darwish IA.
    Medicina (Kaunas); 2023 Oct 12; 59(10):. PubMed ID: 37893531
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Spectrophotometric Study of Charge-Transfer Complexes of Ruxolitinib with Chloranilic Acid and 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone: An Application to the Development of a Green and High-Throughput Microwell Method for Quantification of Ruxolitinib in Its Pharmaceutical Formulations.
    Aljaber KA, Darwish IA, Al-Hossaini AM.
    Molecules; 2023 Nov 30; 28(23):. PubMed ID: 38067605
    [Abstract] [Full Text] [Related]

  • 6. Development of Novel Micellar-Enhanced High-Throughput Microwell Spectrofluorimetric Method for Quantification of Lorlatinib: Application to In Vitro Drug Release and Analysis of Urine Samples.
    Al-Hossaini AM, Darwish HW, Bakheit AH, Darwish IA.
    Pharmaceuticals (Basel); 2023 Sep 06; 16(9):. PubMed ID: 37765067
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases.
    Naito T, Shiraishi H, Fujiwara Y.
    Jpn J Clin Oncol; 2021 Jan 01; 51(1):37-44. PubMed ID: 33147606
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Lorlatinib for the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer.
    Yang J, Gong W.
    Expert Rev Clin Pharmacol; 2019 Mar 01; 12(3):173-178. PubMed ID: 30657349
    [Abstract] [Full Text] [Related]

  • 11. Spectrophotometric Investigations of Charge Transfer Complexes of Tyrosine Kinase Inhibitors with Iodine as a σ-Electron Acceptor: Application to Development of Universal High-Throughput Microwell Assay for Their Determination in Pharmaceutical Formulations.
    Darwish IA, Darwish HW, Ali AM, Almutairi HS.
    Medicina (Kaunas); 2023 Apr 17; 59(4):. PubMed ID: 37109733
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. An update on lorlatinib: a novel first line treatment for ALK-positive advanced lung cancer.
    Riudavets M, Planchard D.
    Expert Opin Pharmacother; 2023 Feb 17; 24(3):291-299. PubMed ID: 36542835
    [Abstract] [Full Text] [Related]

  • 14. Lorlatinib for the treatment of patients with non-small cell lung cancer.
    Akamine T, Toyokawa G, Tagawa T, Yamazaki K, Seto T, Takeo S, Mori M.
    Drugs Today (Barc); 2019 Feb 17; 55(2):107-116. PubMed ID: 30816885
    [Abstract] [Full Text] [Related]

  • 15. Charge-Transfer Complex of Linifanib with 2,3-dichloro-3,5-dicyano-1,4-benzoquinone: Synthesis, Spectroscopic Characterization, Computational Molecular Modelling and Application in the Development of Novel 96-microwell Spectrophotometric Assay.
    Darwish IA, Khalil NY, Alsaif NA, Herqash RN, Sayed AYA, Abdel-Rahman HM.
    Drug Des Devel Ther; 2021 Feb 17; 15():1167-1180. PubMed ID: 33737805
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor.
    Lee J, Sun JM, Lee SH, Ahn JS, Park K, Choi Y, Ahn MJ.
    Clin Lung Cancer; 2019 May 17; 20(3):215-221. PubMed ID: 30683630
    [Abstract] [Full Text] [Related]

  • 17. Three Innovative Green and High-Throughput Microwell Spectrophotometric Methods for the Quantitation of Ceritinib, a Potent Drug for the Treatment of ALK-Positive Non-Small Cell Lung Cancer: An Application to the Analysis of Capsules and Drug Uniformity Testing.
    Abuhejail RM, Alzoman NZ, Darwish IA.
    Molecules; 2023 Oct 12; 28(20):. PubMed ID: 37894533
    [Abstract] [Full Text] [Related]

  • 18. Clinical Management of Adverse Events Associated with Lorlatinib.
    Bauer TM, Felip E, Solomon BJ, Thurm H, Peltz G, Chioda MD, Shaw AT.
    Oncologist; 2019 Aug 12; 24(8):1103-1110. PubMed ID: 30890623
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of first-line treatments for patients with advanced anaplastic lymphoma kinase mutated, non-small cell cancer: A systematic review and network meta-analysis.
    Peng Y, Zhao Q, Liao Z, Ma Y, Ma D.
    Cancer; 2023 Apr 15; 129(8):1261-1275. PubMed ID: 36748799
    [Abstract] [Full Text] [Related]

  • 20. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
    Shaw AT, Felip E, Bauer TM, Besse B, Navarro A, Postel-Vinay S, Gainor JF, Johnson M, Dietrich J, James LP, Clancy JS, Chen J, Martini JF, Abbattista A, Solomon BJ.
    Lancet Oncol; 2017 Dec 15; 18(12):1590-1599. PubMed ID: 29074098
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.